| tips : |
Žurnāls |
| interneta saite : |
http://www.currenttherapeuticres.com/article/S0011-393X(15)00016-8/abstract |
|
| pētniecības grupas : |
San Francisco - Theravance Biopharma |
| Autori : |
Gu Z, Parra C, Wong A, Nguyen A, Cheung R, Catalano T. |
| Nosaukums : |
Post-reconstitution Stability of Telavancin with Commonly Used Diluents and Intravenous Infusion Solutions. |
| Numurs : |
Current Ther Res ; 77: 105-110. 2015 |
|
| Pierādījumu līmeni : |
|
| fizikālā stabilitāte : |
|
| ķīmiskā stabilitāte : |
|
| citas metodes : |
|
| komentāri : |
| Degradēšanās produkti identificēti un noteikts to daudzums |
|
Saraksti
 Telavancin hydrochloride
|
 |
 |
 |
 |
15 mg/ml |
2-8°C |
 |
| 7 |
 |
|
|
|
|
|
15 mg/ml |
20-25°C |
 |
| 12 |
 |
|
|
|
|
 |
15 mg/ml |
2-8°C |
|
| 7 |
|
|
|
|
|
|
15 mg/ml |
20-25°C |
|
| 12 |
|
|
|
|
 |
|
0.6 mg/ml |
2-8°C |
|
| 7 |
|
|
|
|
|
|
0.6 mg/ml |
20-25°C |
|
| 12 |
|
|
|
|
|
|
8 mg/ml |
2-8°C |
|
| 7 |
|
|
|
|
|
|
8 mg/ml |
20-25°C |
|
| 12 |
|
|
|
|
|
 |
0.6 mg/ml |
2-8°C |
|
| 7 |
|
|
|
|
|
|
0.6 mg/ml |
20-25°C |
|
| 12 |
|
|
|
|
|
|
8 mg/ml |
2-8°C |
|
| 7 |
|
|
|
|
|
|
8 mg/ml |
20-25°C |
|
| 12 |
|
|
|
|
|
